Boltin Doron, Zvidi Ibrahim, Raskin Maria, Kayless Hen, Schmilovitz-Weiss Hemda, Gingold-Belfer Rachel, Niv Yaron, Dickman Ram
Division of Gastroenterology, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Gastroenterology, Lod Medical Center, Clalit Health Services, Lod, Israel.
Dig Dis. 2018;36(4):257-263. doi: 10.1159/000489557. Epub 2018 May 23.
Esomeprazole is commonly administered with food; however, clinical data to support this practice are lacking. We aimed to determine the effect of postprandial ingestion of esomeprazole on reflux symptoms among patients with gastroesophageal reflux disease (GERD).
Consecutive patients with GERD adequately controlled with esomeprazole 40 mg daily, entered a 2-week lead-in period during which esomeprazole was administered 30 min before breakfast. Patients were then randomized to continue preprandial ingestion or to ingest esomeprazole following a standardized meal. Outcomes included GERD frequency and severity indices, GERD-health-related quality of life (GERD-HRQL) questionnaire and Short Form 36 (SF-36).
Thirty-two patients (17 [53.1%] men, aged 53.5 ± 17.2 years) were included, and 16 (50%) switched to postprandial ingestion of esomeprazole. GERD frequency and severity decreased in both groups (Δ9.0 ± 7.2 vs. Δ10.0 ± 8.1, p = 0.29; Δ6.6 ± 6.8 vs. Δ10.2 ± 7.4, p = 0.57 in postprandial group vs. controls, for frequency and severity, respectively). GERD-HRQL improved in both study groups to a similar degree (Δ10.7 ± 10.5 vs. Δ10.0 ± 13.8, p = 0.97). All SF-36 subscores increased in both groups to a similar degree. In a mixed linear model, there were no differences between the study groups in the changes observed in GERD frequency (p = 0.49), severity (p = 0.32), and GERD-HRQL (p = 0.98) during the study period.
Switching to postprandial administration of esomeprazole is not associated with deterioration in reflux symptoms among patients with GERD. Esomeprazole seems to remain efficacious when administered after meals.
埃索美拉唑通常与食物一起服用;然而,缺乏支持这种做法的临床数据。我们旨在确定餐后服用埃索美拉唑对胃食管反流病(GERD)患者反流症状的影响。
连续入选每日服用40mg埃索美拉唑病情得到充分控制的GERD患者,进入为期2周的导入期,在此期间埃索美拉唑在早餐前30分钟服用。然后将患者随机分组,继续餐前服用或在标准化餐后服用埃索美拉唑。观察指标包括GERD频率和严重程度指数、GERD健康相关生活质量(GERD-HRQL)问卷和简明健康状况调查量表(SF-36)。
纳入32例患者(17例[53.1%]男性,年龄53.5±17.2岁),16例(50%)改为餐后服用埃索美拉唑。两组的GERD频率和严重程度均降低(频率方面:餐后组与对照组分别为Δ9.0±7.2 vs.Δ10.0±8.1,p=0.29;严重程度方面:餐后组与对照组分别为Δ6.6±6.8 vs.Δ10.2±7.4,p=0.57)。两个研究组的GERD-HRQL均有相似程度的改善(Δ10.7±10.5 vs.Δ10.0±13.8,p=0.97)。两组的所有SF-36子评分均有相似程度的升高。在混合线性模型中,研究期间两组在GERD频率(p=0.49)、严重程度(p=0.32)和GERD-HRQL(p=0.98)的变化方面无差异。
改为餐后服用埃索美拉唑与GERD患者反流症状恶化无关。餐后服用埃索美拉唑似乎仍然有效。